Literature DB >> 10226967

Early results of Bankart repair with a patient-controlled rehabilitation program.

D M McDermott1, L Neumann, S P Frostick, W A Wallace.   

Abstract

A standard protocol for patient rehabilitation after open Bankart procedure has been used in our clinic for more than 5 years. This protocol emphasizes the patient's role in controlling his or her rehabilitation over a 16-week period that results in a full return to work and sport. We have retrospectively reviewed 100 patients (104 shoulders) with a minimum follow-up of 6 months on the program to assess the program's effectiveness. The patients were assessed in terms of their satisfaction in relation to home, work, and sporting activities and the speed with which they returned to work and sport. All patients found the program acceptable. For home activities 100 (96%) of the shoulders were rated good or excellent, for work 94 (90%) were rated good or excellent, and 78 (76%) were rated good or excellent for sport. The shoulders of 5 patients redislocated, and a further 5 patients described ongoing symptoms but no redislocations.

Entities:  

Mesh:

Year:  1999        PMID: 10226967     DOI: 10.1016/s1058-2746(99)90008-3

Source DB:  PubMed          Journal:  J Shoulder Elbow Surg        ISSN: 1058-2746            Impact factor:   3.019


  3 in total

1.  Do patients with minor shoulder instability have a different outcome from those with recurrent anteroinferior instability?

Authors:  Tom Depovere; Nicole Pouliart
Journal:  Eur J Orthop Surg Traumatol       Date:  2019-06-27

2.  Twelve years' experience of the mini-Bankart repair for recurrent anterior dislocation of the shoulder.

Authors:  Alan Cooney; Satyajit Sinha; Alexander Craig Campbell
Journal:  Int J Shoulder Surg       Date:  2009-04

3.  Analysis of shoulder compressive and shear forces during functional activities of daily life.

Authors:  Christian Klemt; Joe A Prinold; Sharon Morgans; Samuel H L Smith; Daniel Nolte; Peter Reilly; Anthony M J Bull
Journal:  Clin Biomech (Bristol, Avon)       Date:  2018-03-14       Impact factor: 2.063

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.